Free Trial
→ Stunning Trump Manhattan Project Now Underway (From Banyan Hill Publishing) (Ad)

Skinvisible Q1 2024 Earnings Report

$0.30 0.00 (0.00%)
As of 01/21/2025
Earnings History

Skinvisible EPS Results

Actual EPS
-$0.06
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Skinvisible Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Skinvisible Announcement Details

Quarter
Q1 2024
Date
5/15/2024
Time
N/A

Conference Call Resources

Skinvisible Earnings Headlines

Skinvisible, Inc. (SKVI)
November 16, 2024 | finance.yahoo.com
Skinvisible, Inc.: Skinvisible Submits Innovative Obesity Patent for Advanced Transdermal Treatment
May 29, 2024 | finanznachrichten.de
Did You See Trump’s Manhattan Project Bombshell?
This secret document contains stunning details about Donald Trump’s very first order of business… the minute he steps back into the White House. Because if what’s in this leaked document is even half true (and trust me, it comes from a very, very credible source)... Trump’s first Executive Order would easily be the boldest, most mind-blowing and daring American initiative ANY U.S. President has launched in over 80 years.
January 22, 2025 | Banyan Hill Publishing (Ad)
Skinvisible Submits Innovative Obesity Patent for Advanced Transdermal Treatment
May 29, 2024 | finance.yahoo.com
ZHUD Zhuding International Limited
May 15, 2024 | seekingalpha.com
Skinvisible, Inc.: Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome
February 14, 2024 | finanznachrichten.de
See More Skinvisible Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Skinvisible? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Skinvisible and other key companies, straight to your email.

About Skinvisible

Skinvisible (OTCMKTS:SKVI), together with its subsidiaries, focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over-the-counter, personal skincare, and cosmetic arenas. Its non-dermatological formulations offer solutions for women's health, pain management, and other markets. The company's flagship product is Invisicare, a patented polymer delivery system technology that enhances the delivery of active ingredients for topically applied skin care products. It also develops and licenses prescription and over-the-counter products to pharmaceutical and consumer goods companies; assists pharmaceutical clients in the early development of the formulations; and provides solutions to pharmaceutical companies by reformulating their products coming off patent with a new Invisicare patent, and new product benefits and line extensions. The company was formerly known as Microbial Solutions, Inc. and changed its name to Skinvisible, Inc. in February 1999. Skinvisible, Inc. was incorporated in 1998 and is based in Las Vegas, Nevada.

View Skinvisible Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles